CN116867488A - 用于治疗干性老年性黄斑变性(amd)的组合物 - Google Patents

用于治疗干性老年性黄斑变性(amd)的组合物 Download PDF

Info

Publication number
CN116867488A
CN116867488A CN202180091728.8A CN202180091728A CN116867488A CN 116867488 A CN116867488 A CN 116867488A CN 202180091728 A CN202180091728 A CN 202180091728A CN 116867488 A CN116867488 A CN 116867488A
Authority
CN
China
Prior art keywords
group
alkyl
compound
pharmaceutically acceptable
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180091728.8A
Other languages
English (en)
Chinese (zh)
Inventor
A·卡贾诺
S·卡塔拉诺
M·哈姆比
N·伊佐
G·鲁克
G·里什顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cognition Therapeutics Inc
Original Assignee
Cognition Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cognition Therapeutics Inc filed Critical Cognition Therapeutics Inc
Publication of CN116867488A publication Critical patent/CN116867488A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202180091728.8A 2020-12-11 2021-12-10 用于治疗干性老年性黄斑变性(amd)的组合物 Pending CN116867488A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063124695P 2020-12-11 2020-12-11
US63/124,695 2020-12-11
PCT/US2021/062850 WO2022125925A1 (en) 2020-12-11 2021-12-10 Compositions for treating dry age-related macular degeneration (amd)

Publications (1)

Publication Number Publication Date
CN116867488A true CN116867488A (zh) 2023-10-10

Family

ID=81974688

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180091728.8A Pending CN116867488A (zh) 2020-12-11 2021-12-10 用于治疗干性老年性黄斑变性(amd)的组合物

Country Status (10)

Country Link
US (1) US20240009168A1 (cg-RX-API-DMAC7.html)
EP (1) EP4259129A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023553414A (cg-RX-API-DMAC7.html)
KR (1) KR20230118158A (cg-RX-API-DMAC7.html)
CN (1) CN116867488A (cg-RX-API-DMAC7.html)
AU (1) AU2021396380A1 (cg-RX-API-DMAC7.html)
CA (1) CA3200346A1 (cg-RX-API-DMAC7.html)
IL (1) IL303592A (cg-RX-API-DMAC7.html)
MX (1) MX2023006677A (cg-RX-API-DMAC7.html)
WO (1) WO2022125925A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025055549A1 (en) * 2024-01-24 2025-03-20 Shanghai University of Medicine and Health Sciences An isoindol-sulfilimine compound and use as a sigma-2 receptor inhibitor thereof

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015116923A1 (en) 2014-01-31 2015-08-06 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
ES3063712T3 (en) 2017-05-15 2026-04-20 Cognition Therapeutics Inc Compositions for treating neurodegenerative diseases
ES2969373B2 (es) 2022-10-14 2025-02-06 Igen Biolab Group Ag Composicion obtenida de lisados de microorganismos probioticos para uso en el tratamiento y/o prevencion de las enfermedades degenerativas del ojo
WO2025122753A2 (en) * 2023-12-08 2025-06-12 Cognition Therapeutics, Inc. Compositions and methods for the treatment of niemann-pick disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140378460A1 (en) * 2011-08-25 2014-12-25 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease
CN106163516A (zh) * 2014-01-31 2016-11-23 考格尼申治疗股份有限公司 异吲哚啉组合物和治疗神经变性疾病的方法
CN110869011A (zh) * 2017-05-15 2020-03-06 考格尼申治疗股份有限公司 用于治疗神经退行性疾病的组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
EP1635805A4 (en) * 2003-06-12 2007-08-08 Ms Science Corp SIGMA RECEPTOR LIGANDS FOR NEURONAL REGENERATION AND FUNCTIONAL RE-ESTABLISHMENT
US7829562B2 (en) * 2003-06-12 2010-11-09 M's Science Corporation Sigma ligands for neuronal regeneration and functional recovery
GB0718737D0 (en) * 2007-09-25 2007-11-07 Glaxo Group Ltd Antibodies
BRPI0919920A2 (pt) * 2008-10-22 2016-02-16 Acucela Inc compostos para tratamento de doenças e desordens oftálmicas
US20110269779A1 (en) * 2008-11-18 2011-11-03 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
KR20220142477A (ko) * 2020-02-13 2022-10-21 카그니션 테라퓨틱스, 인코퍼레이티드 인지 저하 환자에서 아밀로이드 베타 단량체 수준을 감소시키는 방법

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140378460A1 (en) * 2011-08-25 2014-12-25 Cognition Therapeutics, Inc. Compositions and methods for treating neurodegenerative disease
CN106163516A (zh) * 2014-01-31 2016-11-23 考格尼申治疗股份有限公司 异吲哚啉组合物和治疗神经变性疾病的方法
CN110869011A (zh) * 2017-05-15 2020-03-06 考格尼申治疗股份有限公司 用于治疗神经退行性疾病的组合物

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025055549A1 (en) * 2024-01-24 2025-03-20 Shanghai University of Medicine and Health Sciences An isoindol-sulfilimine compound and use as a sigma-2 receptor inhibitor thereof
US12371405B1 (en) 2024-01-24 2025-07-29 Shanghai University of Medicine and Health Sciences Isoindol-sulfilimine compound and use as a sigma-2 receptor inhibitor thereof
AU2024339613B2 (en) * 2024-01-24 2025-11-06 Shanghai University of Medicine and Health Sciences An isoindol-sulfilimine compound and use as a sigma-2 receptor inhibitor thereof

Also Published As

Publication number Publication date
KR20230118158A (ko) 2023-08-10
AU2021396380A1 (en) 2023-06-22
CA3200346A1 (en) 2022-06-16
EP4259129A4 (en) 2024-11-27
IL303592A (en) 2023-08-01
WO2022125925A1 (en) 2022-06-16
MX2023006677A (es) 2023-06-27
JP2023553414A (ja) 2023-12-21
US20240009168A1 (en) 2024-01-11
EP4259129A1 (en) 2023-10-18

Similar Documents

Publication Publication Date Title
US20240009168A1 (en) Compositions for treating dry age-related macular degeneration (amd)
US10987400B2 (en) Methods for the treatment of glaucoma and age-related macular degeneration by a peptide D-TRP-AIB
US11981636B2 (en) Compositions for treating neurodegenerative diseases
KR20230159546A (ko) 신경학적 질환을 치료하기 위한 조성물 및 방법
EP3756665B1 (en) Interval therapy for the treatment of eye diseases
AU2013274582A1 (en) Therapeutic formulation and methods of treatment
AU2013291970B2 (en) Baclofen and acamprosate based therapy of Macular Degeneration disorders
JP7706376B2 (ja) 神経修復方法
WO2025122753A2 (en) Compositions and methods for the treatment of niemann-pick disease
RU2792562C2 (ru) Композиции для лечения нейродегенеративных заболеваний
KR20260049797A (ko) 경도 인지 장애 치료를 위한 병용 요법의 치료제 조성물 및 사용 방법
HK40043513A (en) Interval therapy for the treatment of eye diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination